- This high-quality test can help to reliably triage patients at the point of care and offer immediate reassurance of prior infection
- A small blood sample, that can be easily collected from a minimally invasive finger prick by a healthcare professional, is sufficient to perform the test when venous blood draw is less accessible or suboptimal for the patient
- Portable testing kit enables its convenient use at versatile point of care locations, or in resource-limited settings
Basel, 28 July 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced the launch of the SARS-CoV-2 Rapid Antibody Test in markets accepting the CE Mark. The launch is a partnership with SD Biosensor Inc., with whom Roche has a global distribution agreement. Our partner, SD Biosensor is actively working on an Emergency Use Authorisation (EUA)1 submission to the U.S. Food and Drug Administration (FDA).
This newly developed SARS-CoV-2 Rapid Antibody Test is for use in point of care settings and can help healthcare professionals identify patients that have developed antibodies against SARS-CoV-2, indicating prior infection. The test is part of the comprehensive Roche diagnostic portfolio to help healthcare systems combat COVID-19, which also includes molecular, serology and digital solutions.
The SARS-CoV-2 Rapid Antibody Test can be performed by healthcare professionals in a number of settings outside clinical labs and near to the patient. This is beneficial in situations where timely decisions are needed, laboratory SARS-CoV-2 testing is not available, or finger prick sampling is the better option over a venous blood draw.
Thomas Schinecker, CEO of Roche Diagnostics, stated that, “We have a global responsibility to help better manage the COVID-19 health crisis and provide reliable solutions to our patients when and where needed. We are proud to have a reliable and high quality antibody test for the point of care now included in our COVID-19 diagnostic portfolio.”